My God, first of all, people in supposed pain are going to put a pill in their hospital gown? Seriously? This argument makes little sense and could be applied to any drug not IV related. Maybe the nurse should have checked to see that the woman actually swallowed the percoset pills and didn't just put them under her tongue and pretend to swallow them, also. Otherwise, maybe it will end up in her pocket.
Just curious as Abstral is a sublingual pill of Fentanyl, which of course is not as strong as Zalviso. Our ACRX1, being strictly provided in controlled settings, should be approved, I would think. Would really be surprised if it isn't with the feedback from the doctors and nurses to go along with the patients. With the devices that the company has created to help monitor the use and potential abuse, I feel like they are trying to address the potential concerns the FDA would have.
Am I reading the CT correctly that the information disclosed in the CT will not be made available until that time?
"Accordingly, excluded information from the following exhibit
will not be released to the public for the time period specified:
Exhibit 10.1 through December 31, 2016"
Stillondgo, don't you get all over people for alleged pumping? I don't think any of those people come close to pumping as much as this post claims. Plus, your history as a poster seems to be nothing but putting posters down.
I don't understand the concern of abuse. It is going to be distributed in a hospital setting and though the patient can self administer, it is on a timed availability. It is not being prescribed so the abuse factor is irrelevant, IMO. It is much easier to deal and abuse OxyContin, Rytalin, and/or Oxycodone since those are prescribed. The fact that it is delivered in a controlled and supervised setting already minimizes the concern, doesn't it? What am I missing?
It darn well better. I have been holding as I will be getting a bigger part of my holdings as LTCG this week, but have been missing out on many other stocks hitting good gains.
Interestingly, Symon, a well known SNTS basher, did mention that SNTS was going to be bought out by Salix an hour before close. Though that may indicate he knew something with SNTS, not sure if one can assume he also knows something with ACRX.
Best get an Iowan in here. lol Wimusky, your points are pretty accurate. I bought in this week and though there is never a sure thing, I sure like the research behind it and the medical need that it can provide. The fact that not only does the pain relief mimic that of morphine, but the delivery system provides just as quick relief from the symptoms is pretty intriguing. In addition, when you start thinking about pain relief being provided at roadside accidents, on the battlefield, to burn victims, and also alleviates the problems and discomfort associated with having an IV, it makes one think that the market value is very good. My question is whether this is a drug that could also be prescribed for women during birth? I know that Sufentanil is already provided to pregnant women in the form of an epidural so didn't know what complications or concerns that would have. I also think it serves a role in providing many people with relief of severe migraines that require medical attention. I think the thing that is more attractive at this point is that this will be controlled and that it will not be prescribed. Thus, we don't have to deal with many of the FDA concerns regarding abuse.
Please, someone correct me if I am wrong.
Will that be a big boost to the industry?
So what potential drawbacks could there be to Zalviso approval being that there is an abuse system already built in, it has shown positive results in 3 phase III trials, and it is already an approved drug in the form of an IV? As Scott Matusow put it, "So, it's important that AcelRx has anti-abuse deterrents built into its solution". It is not a drug like Hydrocodone or Oxycodone that is prescribed, right? It is not provided outside of a medical institution, right? Where is the concern for abuse? What am I missing. It is hard to imagine why this drug wouldn't be approved so I am trying to brainstorm here.
As long as questions are asked and people can stop feeling paranoid that someone is bashing the stock, I think it makes for good discussion and information to other board members. My understanding is that Zalviso is meant for hospital control. Is that right, Kitty? Reading situations in the PR that Zalviso could be used such as administering roadside, in an ambulance, on the battlefield, or to even burn victims, are great examples, imo, as to how this product can improve pain management in ways an IV couldn't be used. I do feel abuse is a concern, but it is with any pain management drug. My question is, am I correct in that this drug is controlled by medical personnel or is provided in hospitals, but not for out of hospital use?
I was involved with Yahoo a few years back when Microsoft tried to buy them out at $31 a share, a bid that eventually was turned down, but that was 50% above their price. That was a situation where it was smart to take the money. Though Yahoo has done well and is now over $30, if you recall, the company was a wreck at that time. If the deal would ever fall through here with SNTS, which it won't, Santarus investors would be fine and would continue to do well with the company.
Everyone has an opinion, but I plan to hold and let the dust settle on this one. If this were a company that wasnt as secure as SNTS is, I might sell and walk away. My understanding from talking to an employee of SNTs this evening is that the companies will merge after the new year. We'll find out more details in the coming days.
Kitty, though you may have been part of a buyout where another offer has come in, I haven't been so lucky. Man, I was a part of Kos when Abbot bought them out at a 56% premium. That was a great deal. I would feel much better with an offering at $40 pps. With the indications and potential new treatments for Uceris, San-300, and the new drugs coming through the pipeline, I really think $32 was not in the best interest of the SH.
I know it might be crazy for some to believe, but I am disappointed, actually. I've really enjoyed following this company and was really looking forward to the years to come, especially finding out the results of Sans-300 phase IIa. SNTS was the gift that kept on giving, really. I mean, it is difficult to find a company that provides the results like they did. When my sights were set on seeing it surpass new milestones and much higher pps, it is kind of a letdown. Had strongly contemplated buying another 1,000 shares today and thought I would wait til after earnings. lol Son of a...... I appreciate all of the insight fellow board members provided and will miss my fixation with checking these boards. Hope to catch on with you on another winner in the near future.
Though that is good news, just so people aren't mislead, those results were shown only in animal models at this time. Good news, but still very early stages.
If sales of Uceris are approximately 21, Glumetza at 45, and Cycloset and Fenoglide are around 8, I am a little nervous about Zegerid that saw a loss in sales of 3 mil from 24 to 21, though the 8% price increase will help here. If all else stays the same, we still come in around 95, which should beat.